Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS)Citation formats

  • Authors:
  • Valentine Charlton-Menys
  • D. John Betteridge
  • Helen Colhoun
  • John Fuller
  • Michael France
  • And 7 others
  • External authors:
  • Graham A. Hitman
  • Shona J. Livingstone
  • H. Andrew W Neil
  • Connie B. Newman
  • Michael Szarek
  • David A. DeMicco
  • Paul N. Durrington

Standard

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS). / Charlton-Menys, Valentine; Betteridge, D. John; Colhoun, Helen; Fuller, John; France, Michael; Hitman, Graham A.; Livingstone, Shona J.; Neil, H. Andrew W; Newman, Connie B.; Szarek, Michael; DeMicco, David A.; Durrington, Paul N.

In: Clinical Chemistry, Vol. 55, No. 3, 01.03.2009, p. 473-480.

Research output: Contribution to journalArticlepeer-review

Harvard

Charlton-Menys, V, Betteridge, DJ, Colhoun, H, Fuller, J, France, M, Hitman, GA, Livingstone, SJ, Neil, HAW, Newman, CB, Szarek, M, DeMicco, DA & Durrington, PN 2009, 'Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS)', Clinical Chemistry, vol. 55, no. 3, pp. 473-480. https://doi.org/10.1373/clinchem.2008.111401

APA

Charlton-Menys, V., Betteridge, D. J., Colhoun, H., Fuller, J., France, M., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M., DeMicco, D. A., & Durrington, P. N. (2009). Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS). Clinical Chemistry, 55(3), 473-480. https://doi.org/10.1373/clinchem.2008.111401

Vancouver

Author

Charlton-Menys, Valentine ; Betteridge, D. John ; Colhoun, Helen ; Fuller, John ; France, Michael ; Hitman, Graham A. ; Livingstone, Shona J. ; Neil, H. Andrew W ; Newman, Connie B. ; Szarek, Michael ; DeMicco, David A. ; Durrington, Paul N. / Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS). In: Clinical Chemistry. 2009 ; Vol. 55, No. 3. pp. 473-480.

Bibtex

@article{fe3232f9fbdb4135ad03c76d284b6573,
title = "Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS)",
abstract = "LDL can vary considerably in its cholesterol content; thus, lowering LDL cholesterol (LDLC) as a goal of statin treatment implies the existence of considerable variation in the extent to which statin treatment removes circulating LDL particles. This consideration is particularly applicable in diabetes mellitus, in which LDL is frequently depleted of cholesterol. methods: Type 2 diabetes patients randomly allocated to 10 mg/day atorvastatin (n = 1154) or to placebo (n = 1196) for 1 year were studied to compare spontaneous and statin-induced apolipoprotein B (apo B) concentrations (a measure of LDL particle concentration) at LDLC and non-HDL cholesterol (non-HDLC) concentrations proposed as statin targets in type 2 diabetes. results: Patients treated with atorvastatin produced lower serum apo B concentrations at any given LDLC concentration than patients on placebo. An LDLC concentration of 1.8 mmol/L (70 mg/dL) during atorvastatin treatment was equivalent to a non-HDLC concentration of 2.59 mmol/L (100 mg/dL) or an apo B concentration of 0.8 g/L. At the more conservative LDLC targets of 2.59 mmol/L (100 mg/dL) and 3.37 mmol/L (130 mg/dL) for non-HDLC, however, the apo B concentration exceeded the 0.9-g/L value anticipated in the recent Consensus Statement from the American Diabetes Association and the American College of Cardiology. CONCLUSIONS: The apo B concentration provides a more consistent goal for statin treatment than the LDLC or non-HDLC concentration. {\textcopyright} 2008 American Association for Clinical Chemistry.",
keywords = "Adult, Aged, blood: Apolipoproteins B, blood: Cholesterol, HDL, blood: Cholesterol, LDL, blood: Diabetes Mellitus, Type 2, Female, therapeutic use: Heptanoic Acids, Humans, metabolism: Hydroxymethylglutaryl CoA Reductases, therapeutic use: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, therapeutic use: Pyrroles",
author = "Valentine Charlton-Menys and Betteridge, {D. John} and Helen Colhoun and John Fuller and Michael France and Hitman, {Graham A.} and Livingstone, {Shona J.} and Neil, {H. Andrew W} and Newman, {Connie B.} and Michael Szarek and DeMicco, {David A.} and Durrington, {Paul N.}",
year = "2009",
month = mar,
day = "1",
doi = "10.1373/clinchem.2008.111401",
language = "English",
volume = "55",
pages = "473--480",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS)

AU - Charlton-Menys, Valentine

AU - Betteridge, D. John

AU - Colhoun, Helen

AU - Fuller, John

AU - France, Michael

AU - Hitman, Graham A.

AU - Livingstone, Shona J.

AU - Neil, H. Andrew W

AU - Newman, Connie B.

AU - Szarek, Michael

AU - DeMicco, David A.

AU - Durrington, Paul N.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - LDL can vary considerably in its cholesterol content; thus, lowering LDL cholesterol (LDLC) as a goal of statin treatment implies the existence of considerable variation in the extent to which statin treatment removes circulating LDL particles. This consideration is particularly applicable in diabetes mellitus, in which LDL is frequently depleted of cholesterol. methods: Type 2 diabetes patients randomly allocated to 10 mg/day atorvastatin (n = 1154) or to placebo (n = 1196) for 1 year were studied to compare spontaneous and statin-induced apolipoprotein B (apo B) concentrations (a measure of LDL particle concentration) at LDLC and non-HDL cholesterol (non-HDLC) concentrations proposed as statin targets in type 2 diabetes. results: Patients treated with atorvastatin produced lower serum apo B concentrations at any given LDLC concentration than patients on placebo. An LDLC concentration of 1.8 mmol/L (70 mg/dL) during atorvastatin treatment was equivalent to a non-HDLC concentration of 2.59 mmol/L (100 mg/dL) or an apo B concentration of 0.8 g/L. At the more conservative LDLC targets of 2.59 mmol/L (100 mg/dL) and 3.37 mmol/L (130 mg/dL) for non-HDLC, however, the apo B concentration exceeded the 0.9-g/L value anticipated in the recent Consensus Statement from the American Diabetes Association and the American College of Cardiology. CONCLUSIONS: The apo B concentration provides a more consistent goal for statin treatment than the LDLC or non-HDLC concentration. © 2008 American Association for Clinical Chemistry.

AB - LDL can vary considerably in its cholesterol content; thus, lowering LDL cholesterol (LDLC) as a goal of statin treatment implies the existence of considerable variation in the extent to which statin treatment removes circulating LDL particles. This consideration is particularly applicable in diabetes mellitus, in which LDL is frequently depleted of cholesterol. methods: Type 2 diabetes patients randomly allocated to 10 mg/day atorvastatin (n = 1154) or to placebo (n = 1196) for 1 year were studied to compare spontaneous and statin-induced apolipoprotein B (apo B) concentrations (a measure of LDL particle concentration) at LDLC and non-HDL cholesterol (non-HDLC) concentrations proposed as statin targets in type 2 diabetes. results: Patients treated with atorvastatin produced lower serum apo B concentrations at any given LDLC concentration than patients on placebo. An LDLC concentration of 1.8 mmol/L (70 mg/dL) during atorvastatin treatment was equivalent to a non-HDLC concentration of 2.59 mmol/L (100 mg/dL) or an apo B concentration of 0.8 g/L. At the more conservative LDLC targets of 2.59 mmol/L (100 mg/dL) and 3.37 mmol/L (130 mg/dL) for non-HDLC, however, the apo B concentration exceeded the 0.9-g/L value anticipated in the recent Consensus Statement from the American Diabetes Association and the American College of Cardiology. CONCLUSIONS: The apo B concentration provides a more consistent goal for statin treatment than the LDLC or non-HDLC concentration. © 2008 American Association for Clinical Chemistry.

KW - Adult

KW - Aged

KW - blood: Apolipoproteins B

KW - blood: Cholesterol, HDL

KW - blood: Cholesterol, LDL

KW - blood: Diabetes Mellitus, Type 2

KW - Female

KW - therapeutic use: Heptanoic Acids

KW - Humans

KW - metabolism: Hydroxymethylglutaryl CoA Reductases

KW - therapeutic use: Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Male

KW - Middle Aged

KW - therapeutic use: Pyrroles

U2 - 10.1373/clinchem.2008.111401

DO - 10.1373/clinchem.2008.111401

M3 - Article

VL - 55

SP - 473

EP - 480

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 3

ER -